TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1513728
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (for full thickness wounds)
Study: 3010383
Drug: Cyclazocine (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclazocine (0.125 mg/70 kg)
Study: 3010383
Drug: Cyclazocine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclazocine (0.25 mg/70 kg)
Study: 3010383
Drug: Cyclazocine (0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclazocine (0.50 mg/70 kg)
Study: 31272957
Drug: Systemic corticosteroid
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic corticosteroid treatment (n=51; range 9-115 months)
Study: 23918617
Drug: +360 kcal/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: +360 kcal/d supplement for 6 months
Study: 18191355
Drug: Centella asiatica
Normalized name: Centella asiatica
DrugBank: Centella asiatica (DB14256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centella asiatica (250, 500, and 750 mg once daily for 2 months)
Study: 16874170
Drug: Pentavalent DTPw-HBV/Hib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent DTPw-HBV/Hib vaccines with 10, 5, or 2.5 microg of PRP conjugated to tetanus toxoid
Study: 16874170
Drug: Pentavalent DTPw-HBV/Hib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent DTPw-HBV/Hib vaccines
Study: 14513421
Drug: Valacyclovir (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir (500 mg twice daily) and Placebo
Study: 3835164
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg Gentamycin and 600 mg Lincomycin intramuscularly, two hours preoperatively, and every eight hours postoperatively for three days
Study: 3835164
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg Gentamycin and 600 mg Clindamycin intramuscularly, two hours preoperatively, and every eight hours postoperatively for three days
Study: 3835164
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg Gentamycin and 500 mg Metronidazole given over 20 minutes, two hours preoperatively, and every eight hours postoperatively for three days
Study: 31310600
Drug: Intranasal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal sufentanil (INS) 0.3 μg/kg with additional doses of 0.15 μg/kg at 10 and 20 minutes if NRS > 3
Study: 31310600
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (IVM) 0.1 mg/kg with additional doses of 0.05 mg/kg at 10 and 20 minutes if NRS > 3
Study: 27450277
Drug: DCV 60
Normalized name: DCV
DrugBank: AV-COVID-19 (DB15802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCV 60 mg once daily for 5 days
Study: 27450277
Drug: DTG 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTG 50 mg once daily for 5 days
Study: 22734377
Drug: Indometacin suppository
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin suppository
Study: 18984888
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation of a combination of 2.5 mg of folic acid, 50 mg of vitamin B(6), and 1 mg of vitamin B(12) (n = 2721)
Study: 15894946
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg per day
Study: 10424277
Drug: alpha2b-interferon alone
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha2b-interferon alone (6 months at 6 MU followed by 6 months at 3 MU three times weekly)
Study: 10424277
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ribavirin and alpha2b-interferon (2 months ribavirin followed by 2 months of ribavirin with alpha2b-interferon at 1.0 or 1.2 g daily)
Study: 7574741
Drug: Intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial chemotherapy (group A) with high-dose intermittent 5-FU infusion at 1,000 mg/m2 for 5 hours a week.
Study: 7574741
Drug: Usual hepatectomy
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual hepatectomy (group B) without intra-arterial chemotherapy.
Study: 2153478
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg intravenous enalaprilat
Study: 28112528
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (720 mg eicosapentaenoic acid plus 480 mg docosahexaenoic acid)
Study: 21272188
Drug: Low-dose insulin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose insulin infusion (0.5 mU/kg/min)
Study: 21272188
Drug: Low-dose insulin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose insulin infusion (1.5 mU/kg/min)
Study: 21272188
Drug: High-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose insulin infusion (3.0 mU/kg/min)
Study: 21272188
Drug: High-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose insulin infusion (5.0 mU/kg/min)
Study: 21272188
Drug: High-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose insulin infusion (3.0 and 5.0 mU/kg/min)
Study: 12752054
Drug: Topical latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical latanoprost 0.005%
Study: 12752054
Drug: Topical brimonidine
Normalized name: brimonidine Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical brimonidine 0.2%
Study: 9307711
Drug: Beta carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta carotene (360 mg/week x 12 months)
Study: 3547572
Drug: Intramuscular immunoglobulins
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular immunoglobulins against Pseudomonas aeruginosa
Study: 3547572
Drug: J5 antiserum
Approvals — FDA: no, EMA: no, PMDA: no
Description: J5 antiserum administered prophylactically to high-risk surgical patients
Study: 29239677
Drug: Conventional Physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Physical Therapy Group (CPTG)
Study: 23483627
Drug: istradefylline 40
Normalized name: istradefylline 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: istradefylline 40 mg/day
Study: 11462946
Drug: 5-day course
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day course of leucovorin (200 mg/m2/day), 5-fluorouracil (375 mg/m2/day), and cisplatin (15 mg/m2/day) repeated every 21 days
Study: 9781723
Drug: Enalaprilat (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat (0.25 mg/hr)
Study: 8143426
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g of glucose in 300 ml of water (n = 8)
Study: 8143426
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of fat in 250 ml of water (n = 8)
Study: 8143426
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g of lean meat corresponding to 40 g of protein with 250 ml of water (n = 8)
Study: 8143426
Drug: 300 ml
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ml of water only (n = 7)
Study: 3262175
Drug: Postoperative infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative infusion of a 3% amino acid solution
Study: 3262175
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no amino acid infusion)
Study: 31871950
Drug: Theracurmin® (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theracurmin® (180 mg daily for 6 months)
Study: 28483174
Drug: Multimodal Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimodal Intervention (MI) including care from psychiatry, general medicine, neuropsychology, family therapy, and occupational therapy
Study: 28483174
Drug: Traditional Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional Intervention (TI) including care from psychiatry and general medicine
Study: 20456557
Drug: Two-compound scalp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-compound scalp formulation (calcipotriol 50 μg/g and betamethasone 0.5 mg/g)
Study: 10874228
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment group (Sotalol and Amiodarone combined)
Study: 9107560
Drug: Bisoprolol (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (titrated up to 10 mg, starting with 1.25 mg daily)
Study: 3516704
Drug: Nifedipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (5 mg tds to 15 mg tds)
Study: 28065235
Drug: telmisartan +
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: telmisartan + analog traditional Chinese medicine (TA)
Study: 28065235
Drug: traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: traditional Chinese medicine + analog telmisartan (TCMA)
Study: 28065235
Drug: telmisartan +
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: telmisartan + traditional Chinese medicine (TTCM)
Study: 19823111
Drug: SPL7013 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPL7013 Gel 0.5% (N = 8)
Study: 19823111
Drug: SPL7013 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPL7013 Gel 1% (N = 8)
Study: 19823111
Drug: SPL7013 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPL7013 Gel 3% (N = 9)
Study: 19823111
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (N = 12)
Study: 11672461
Drug: Amodiaquine (AQ)
Normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amodiaquine (AQ) at 10 mg/kg per day for 3 days
Study: 11672461
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) at 10 mg/kg per day for 3 days
Study: 9828551
Drug: Pyridoxine hydrochloride
Normalized name: Pyridoxine Hydrochloride
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridoxine hydrochloride 100 mg daily one hour before radiation therapy for 7 days
Study: 26302024
Drug: Probiotics (cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (cultured Lactobacillus subtilis/Streptococcus faecium) 1500 mg/day for 7 days
Study: 22007715
Drug: Control (non-malaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (non-malaria comparator vaccine)
Study: 17288757
Drug: Tirofiban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban (10 microg/kg bolus i.v. followed by 0.15 microg x kg(‐1) x min(‐1) for 36 hours) administered early before PCI
Study: 17288757
Drug: Tirofiban administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban administered late before PCI
Study: 15728061
Drug: Esmolol (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (bolus of 1 mg/kg and then 0.25 mg x kg(‐1) x min(‐1))
Study: 15728061
Drug: Landiolol (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (bolus of 0.125 mg/kg and then 0.04 mg x kg(‐1) x min(‐1))
Study: 2008946
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine sulfate (ITMS) 15 micrograms/kg
Study: 7042252
Drug: Propantheline (optimally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propantheline (optimally effective dose)
Study: 24945085
Drug: Guanfacine extended
Normalized name: Guanfacine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine extended release (GXR) adjunctive to psychostimulant (1-4 mg/d)
Study: 24945085
Drug: Placebo adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo adjunctive to psychostimulant
Study: 22972364
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin therapy (pitavastatin or atorvastatin)
Study: 19167094
Drug: Unsupported online
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupported online computerized cognitive behavioral therapy (CCBT)
Study: 15213077
Drug: 50 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg.kg(‐1) of tranexamic acid at induction of anesthesia (Group B)
Study: 15213077
Drug: 10 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg.kg(‐1) at induction followed by an infusion of 1 mg.kg(‐1).h(‐1) (Group C)
Study: 15213077
Drug: 10 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg.kg(‐1) at induction, 10 mg.kg(‐1) on bypass, and 10 mg.kg(‐1) after protamine (Group D)
Study: 15213077
Drug: 20 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg.kg(‐1) at induction and again after protamine (Group E)
Study: 9879617
Drug: Magnesium infusions
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium infusions in acute myocardial infarction
Study: 7982129
Drug: Placebo (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3.5 ml saline)
Study: 7982129
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg ANP (dissolved in 3.5 ml saline)
Study: 7982129
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg ANP (dissolved in 3.5 ml saline)
Study: 7982129
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg ANP
Study: 7982129
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg ANP
Study: 2660373
Drug: N-acetylcysteine (Mucomyst)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (Mucomyst) administered systemically in the recommended dosage
Study: 21320549
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of PCV7
Study: 21344811
Drug: Electro-acupuncture (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-acupuncture (10 sessions, twice a week)
Study: 17634060
Drug: Ganaxolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganaxolone (1 mg/kg, b.i.d. to 12 mg/kg t.i.d. over 16 days, followed by 8 weeks maintenance)
Study: 12095015
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion at 0.5 microg kg(‐1) min(‐1)
Study: 12095015
Drug: Fentanyl bolus
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl bolus dose of 1.5 microg kg(‐1)
Study: 7440694
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg, iv) at 2300 h
Study: 7440694
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg, iv) at 1100 h
Study: 31384636
Drug: Ropinirole hydrochloride
Normalized name: Ropinirole Hydrochloride
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ropinirole hydrochloride extended-release tablet (Requip CR) at 2- to 16-mg doses
Study: 31384636
Drug: Ropinirole hydrochloride
Normalized name: Ropinirole Hydrochloride
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ropinirole hydrochloride extended-release tablet (Requip CR)
Study: 21966817
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (20 mg, vaginally every 6 hours, maximum 3 times)
Study: 21966817
Drug: Dinoprostone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone (0.5 mcg, vaginally every 6 hours, maximum 3 times)
Study: 21966817
Drug: Dinoprostone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone (0.5 mcg)
Study: 17352450
Drug: Various therapeutic
Normalized name: Various therapeutic radiopharmaceuticals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various therapeutic agents used in the management of Polycythaemia Vera
Study: 9240689
Drug: MDCK-derived vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDCK-derived vaccine
Study: 7962681
Drug: Sustained-release adinazolam
Normalized name: adinazolam
DrugBank: Adinazolam (DB00546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release adinazolam
Study: 14960504
Drug: Ramipril (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (1.25 mg/day)
Study: 11772833
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Leg-Up and Head-Down Tilt
Study: 9620902
Drug: Resistive load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistive load of 3 cm H2O/L/s
Study: 9620902
Drug: Resistive load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistive load of 6 cm H2O/L/s
Study: 9620902
Drug: Resistive loads
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistive loads of 3 and 6 cm H2O/L/s
Study: 15298560
Drug: Standardized house
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized house dust mite immunotherapy (SIT)
Study: 11358645
Drug: HRT+simvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT+simvastatin (10 mg/day)
Study: 11358645
Drug: HRT+bezafibrate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT+bezafibrate (400 mg/day)
Study: 11548225
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulfate 500 mg t.i.d.
Study: 30192326
Drug: Early catheter
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early catheter removal with prazosin 1 mg oral 6 hours before removal
Study: 27888990
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide (2 mg 3 times/day)
Study: 27888990
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (40 mg/day)
Study: 24948549
Drug: Balloon-expandable drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon-expandable drug-eluting stents (DES)
Study: 23910429
Drug: Intensive target-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive target-based medical treatment for cardiac risk factors
Study: 16340193
Drug: MCR +
Normalized name: isosorbide mononitrate Extended Release Oral Tablet [MCR (Mono-Cedocard Retard)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCR + irinotecan (350 mg/m(2)) (group B)
Study: 14639777
Drug: AMMA treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMMA treatments
Study: 1615136
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg sodium pentobarbital (SIN)
Study: 1615136
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg sodium pentobarbital in divided doses (DIV)
Study: 3519416
Drug: Muzolimine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muzolimine (30 mg)
Study: 18716168
Drug: Flavanol-rich dark
Normalized name: dark leaved mugwort pollen extract
DrugBank: Artemisia ludoviciana pollen (DB10762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavanol-rich dark chocolate (FRDC) at 100 g/d for 15 days
Study: 15507173
Drug: Standard axillary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard axillary treatment
Study: 9003262
Drug: Tracheobronchial cytology
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tracheobronchial cytology in patients with inhalation injury
Study: 9003262
Drug: Control patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control patients (no inhalation injury)
Study: 3122528
Drug: Bulk laxatives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bulk laxatives containing stimulant type laxative
Study: 23994107
Drug: Neo-adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-adjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS)
Study: 21947389
Drug: JNJ-Q2 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-Q2 (250 mg, twice a day)
Study: 21947389
Drug: Linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600 mg, twice a day)
Study: 16756534
Drug: High-energy infant
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy infant formula (1 kcal mL(‐1)) at full strength from day 1
Study: 15361886
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (16 mg OD)
Study: 15655136
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg OD)
Study: 11524054
Drug: Hu23F2G (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hu23F2G (low-dose 0.3 mg/kg)
Study: 11524054
Drug: Hu23F2G (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hu23F2G (high-dose 1.0 mg/kg)
Study: 11524054
Drug: Hu23F2G (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hu23F2G (low-dose and high-dose)
Study: 9259500
Drug: Topical Lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Lithium Succinate cream (8% lithium succinate, 0.05% zinc sulphate)
Study: 3102711
Drug: Intravenous gammaglobulin
Normalized name: Human gammaglobulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gammaglobulin therapy (0.5 g/kg/wk for 1 month in group 1 and during intensive care in group 2)
Study: 3102711
Drug: Intravenous gammaglobulin
Normalized name: Human gammaglobulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gammaglobulin therapy
Study: 3102711
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no gammaglobulin therapy)